Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 49

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 49
---
ed restricted stock units at December 31, 2024 |     |           | 1,774,287 |   |     | $                     | 15.58 |

Unamortized share-based compensation for restricted stock units as of December 31, 2024 was$25.8million, which is expected to be recognized over a weighted-average period of2.7years.

<div align='center'>F-31</div>

Restricted Stock Awards

The following table provides a summary of the unvested common stock awards activity during the year ended December 31, 2024.

|                                               |     | Number of 
 Shares    |          |   |     | Weighted Average      
 Grant Date Fair Value 
 Per Share             |       |
|:----------------------------------------------|:----|:----------|---------:|:--|:----|:----------------------|------:|
| Unvested common stock as of December 31, 2023 |     |           |  747,679 |   |     | $                     | 16.00 |
| Vested                                        |     |           | (636,647 | ) |     | $                     | 16.00 |
| Forfeiture                                    |     |           |  (28,751 | ) |     | $                     | 16.00 |
| Unvested common stock as of December 31, 2024 |     |           |   82,281 |   |     | $                     | 16.00 |

Unamortized share-based compensation for restricted stock awards as of December 31, 2024 was$0.5million, which is expected to be recognized over a weighted-average period of0.2years.

2021 Employee Stock Purchase Plan

In May 2021, the board of directors adopted and the stockholders approved the 2021 Employee Stock Purchase Plan, or the ESPP, which became effective on May 26, 2021. A total of603,000shares of common stock were initially reserved for issuance under the ESPP. The number of shares of the common stock reserved for issuance under the ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including, the fiscal year commencing on January 1, 2031, by the lesser of: (a)1% of the total number of outstanding shares of common stock of